Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Metrics to compare | ORKA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORKAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −38.5x | −3.4x | −0.5x | |
PEG Ratio | −0.70 | −0.09 | 0.00 | |
Price / Book | 6.9x | 4.0x | 2.6x | |
Price / LTM Sales | - | 10.3x | 3.2x | |
Upside (Analyst Target) | 11.8% | 76.5% | 47.6% | |
Fair Value Upside | Unlock | 3.0% | 6.1% | Unlock |